Recent Finacing
Recent Raise
Citryll is a Netherlands-based biotech developing monoclonal antibodies (CIT-013/tACPA) that bind citrullinated histone epitopes to inhibit NET formation and treat NET-driven autoimmune and inflammatory diseases.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Citryll.
